Patients with HR−/HER2-, HR+/HER2+ and HR−/HER2+ breast cancers were more likely to have higher tumour grades and a histological type classification of ductal carcinoma than those with HR+/HER2- breast cancer (P < 0.001). This evidence concerns the gene ERBB2 and breast cancer.